SOAT1 and atopic eczema: In addition, inhibition of the JAK-STAT signalling pathway is expected to be a useful therapeutic approach in diseases with impaired barrier functions, such as atopic dermatitis and inflammatory bowel disease, by strengthening cell junctions34–36.